Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients.
Vincenzo RussoRoberta BottinoAntonello D'AndreaAngelo SilverioMarco Di MaioPaolo GolinoGerardo NigroOrazio ValsecchiEmilio AttenaMario Enrico CanonicoGennaro GalassoGuido ParodiFernando ScudieroPublished in: Cardiovascular drugs and therapy (2021)
Overall, 427 patients were included; 87 patients (19%) were in the OAT group. Of them, 54 patients (13%) were on treatment with non-vitamin k oral anticoagulants (NOACs) and 33 (8%) with vitamin-K antagonists (VKAs). OAT patients were older and had a higher rate of hypertension, diabetes, and coronary artery disease compared to No-OAT group. The rate of ARDS at admission (26% vs 28%, P=0.834), or developed during the hospitalization (9% vs 10%, P=0.915), was similar between study groups; in-hospital mortality (22% vs 26%, P=0.395) was also comparable. After balancing for potential confounders by using the propensity score matching technique, no differences were found in term of clinical outcome between OAT and No-OAT patients CONCLUSION: Oral anticoagulation therapy, either NOACs or VKAs, did not influence the risk of ARDS or death in patients hospitalized with COVID-19.
Keyphrases
- end stage renal disease
- coronary artery disease
- ejection fraction
- type diabetes
- chronic kidney disease
- sars cov
- peritoneal dialysis
- bone marrow
- patient reported outcomes
- cardiovascular disease
- emergency department
- physical activity
- coronavirus disease
- adipose tissue
- blood pressure
- mesenchymal stem cells
- aortic valve
- extracorporeal membrane oxygenation
- coronary artery bypass grafting
- replacement therapy
- arterial hypertension